Biospecimen and Pathology Core

摘要 罗斯威尔公园卵巢癌孢子生物标本和病理学核心（BPC）结合了集中的 专业组织处理服务的机制， 拥有最先进的集成信息学基础设施的经验丰富的人员， 跟踪生物标本采集、组织病理学评价和样本的临床注释， 免疫基因组学和其他翻译数据所产生的个别研究项目提出的，在这个 续期申请。核心将收集，去识别，处理，银行，并分发注释，高质量 来自参与SPORE申办的临床研究的患者的肿瘤和血液样品。此外，BPC 将为研究者提供专门的技术和解释性组织病理学服务，包括 在多重免疫组织化学（IHC）和成像质量细胞术（IMC），组织微阵列 构建、激光捕获显微切割、数字成像和切片的定量病理学审查，肿瘤- 浸润淋巴细胞评估、组织QC/QA和下一代测序检测的准备 （全外显子组seq、RNAseq、TCRseq、MethylSEQ），并监督每个生物样本的最佳利用。 核心还将有助于检测患者生物标本，以确定临床试验的合格性， 通过对卵巢肿瘤的详细免疫学注释，直接添加到双向转化科学中。

ABSTRACT The Roswell Park Ovarian Cancer SPORE Biospecimen & Pathology Core (BPC) combines a centralized mechanism for expert tissue handling services and performance of tissue-based assays by highly qualified, experienced personnel with a state-of-the-art integrated informatics infrastructure which provides tools for tracking biospecimen collection, histopathological evaluation, and clinical annotation of samples with linkage to immunogenomic and other translational data generated by the Individual Research Projects proposed in this renewal application. The Core will collect, de-identify, process, bank, and distribute annotated, high-quality tumor and blood samples from patients participating in SPORE-sponsored clinical studies. In addition, the BPC will provide investigators with specialized technical and interpretative histopathology services including expertise in multiplexed immunohistochemistry (IHC) and imaging mass cytometry (IMC), tissue microarray construction, laser capture microdissection, digital imaging, and quantitative pathology review of slides, tumor- infiltrating lymphocytes assessment, tissue QC/QA and preparation for next-gen sequencing-based assays (whole exome seq, RNAseq, TCRseq, MethylSEQ), and oversight on optimal utilization of each biospecimen. The Core will also be instrumental in testing patient biospecimens to determine eligibility for clinical trials and directly add to the bi-directional translational science by a detailed immunological annotation of ovarian tumors.